FDA Approves Dectomax-CA1 for Treatment and Prevention of NWS Infestations in Cattle
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Today, we conditionally approved the first drug for the prevention and treatment of New World screwworm (NWS) larval infestations as well as the prevention of NWS reinfestation for 21 days.
This conditional approval is limited for use in cattle and demonstrates the Agency’s dedication to rapidly facilitating access to important animal health products.”
New World Screwworm infestations, first re-emerging in Central America in 2024, have spread north through Mexico in 2025, with cases now detected as far as Nuevo Leon near the U.S. border.
The outbreak threatens regional cattle industries, prompting livestock movement restrictions, sterile fly release programs, and strict U.S.–Mexico border surveillance.
On September 30, 2025, the U.S. Food and Drug Administration conditionally approved Dectomax-CA1 for the prevention and treatment of New World screwworm (NWS) larval infestations in cattle.
The drug is available as an injectable solution and provides protection against reinfestation for up to 21 days.
Doramectin, the active ingredient, is a macrocyclic lactone that targets the parasite’s nervous system by selectively binding to glutamate-gated chloride channels.
This binding leads to hyperpolarization of nerve and muscle membranes, resulting in paralysis and death of the parasite.
Its longer half-life, due to greater lipophilicity and enhanced tissue distribution, underlies its prolonged activity, which represents a key advantage over other similar agents.
Read more on the topic here.
More on latest FDA approvals in the field of Hematology featured in Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25